ALGOTX
14.3.2023 08:02:19 CET | Business Wire | Press release
European biotech AlgoTx, the developer of first-in-class treatment ATX01 for chemotherapy-induced peripheral neuropathy (CIPN), announced today the success of a €20M Series B fundraising led by Relyens Innovation Santé / Turenne Capital , followed by UI Investissement, and historical investors Bpifrance through its Innobio 2 fund and Omnes Capital. Early and new business angel investors also significantly participated in this financing round, and AlgoTx secured an additional 1M€ in non-dilutive financing. The proceeds will be used to demonstrate the clinical efficacy of ATX01 in neuropathic pain.
Bervin Bouani, Investment Director at Turenne Capital, commented: “We are very proud to lead this strategic financing round to support AlgoTx to continue the clinical development of ATX01 lead candidate that has the potential to significantly improve the lives of patients with neuropathic pain. We look forward to working with Stéphane and his outstanding team to transform AlgoTx into a global pain player.”
Following the demonstration of ATX01’s early clinical safety and low systemic passage in Phase 1, the Phase 2 “ACT” study will now assess ATX01’s ability to reduce pain in adult CIPN patients – a program granted “fast-track” designation by FDA. In parallel, the Phase 2 “EASE” study will explore ATX01’s efficacy in the debilitating pain of erythromelalgia, a program for which ATX01 was granted “Orphan Disease Designation” in the US and Europe.
Stéphane Thiroloix, Founder & CEO of AlgoTx, says: “It is incredibly exciting to start the efficacy trials of ATX01, supported by such a high-profile syndicate of investors. We look forward to enrolling patients in our studies any day now.”
Over half of cancer patients treated with chemotherapy develop CIPN and experience sensory symptoms and pain in the hands and feet: loss of sensitivity, tingling, burning, cold and intense pain can persist for months to years after treatment. It affects over two million patients in the US and Europe and represents a leading cause for modification or interruption of chemotherapy. To this date, no therapeutic approach has offered a satisfactory response for patients and their caregivers, oncologists, neurologists and pain specialists.
« We are very pleased to support the AlgoTx team in the development of ATX01, driven by our belief in its significant impact in the treatment of CIPN and other neuropathic pain. AlgoTx can truly transform the lives of patients suffering from these conditions », says Pauline de Breteuil Senior Partner UI Investissement / FCPI Majycc Innovation Santé.
About AlgoTx
AlgoTx develops novel treatments for complex pain, with lead program ATX01 in Phase 2 in chemotherapy-induced peripheral neuropathy (NCT05593614) and erythromelalgia. More information at www.algotx.com
ACT study : ATX01 for the pain of ChemoTherapy, (NCT05593614). EASE study : Efficacy of ATX01 / Study in Erythromelalgia.
ABOUT TURENNE GROUP/RELYENS INNOVATION SANTÉ
Launched in 2014, Relyens Innovation Santé is is an evergreen venture capital vehicle specializing in health innovation controlled and owned by Relyens, a mutual insurance company specializing in the risk management of health, social and medical players. Relyens is the leading French player in medical civil liability. Advised by Turenne Santé (Health Division of Turenne Group), Relyens Innovation Santé's mission is to support the growth and development phases of innovative companies in the health sector.
Turenne Group, one of the leading private equity companies in France, has been supporting entrepreneurs for 23 years in their company’s innovation, development and transfer projects. As an independent player, the Group has assets of €1.4 billion under management. Its teams, made up of 68 professionals, including 52 investors, based in Paris, Lille (Nord Capital Partenaires), Lyon, Bordeaux, Marseille, Nice and Metz, support 290 business leaders, particularly in the healthcare, hospitality, innovation, BtoB services, and in the digital and impact sectors. With more than €300m, our healthcare team (Turenne Santé) invests across the entire value creation chain for healthcare companies through various investment approaches.
For more information: www.relyens.eu/fr / www.turennecapital.com
About Bpifrance and InnoBio 2
Bpifrance is the French national investment bank: it finances businesses – at every stage of their development – through loans, guarantees, equity investments and export insurances. Bpifrance also provides extra financial services (training, consultancy) to help entrepreneurs meet their challenges (innovation, export).
InnoBio 2 is an investment fund dedicated to life sciences, managed by Bpifrance, which is also one of the LPs alongside Sanofi, Boehringer Ingelheim, Takeda, Ipsen, Servier, BMS, European Investment Fund and Pasteur Mutualité. InnoBio 2, with €203 million, aims to invest in companies developing innovative products and services, close to or in early clinical development, with the objective of bringing them until the clinical proof of concept. InnoBio 2 takes minority equity stake in companies and can lead or co-lead the investment rounds.
For more information, please visit: www.bpifrance.com – Follow us on Twitter : @bpifrance - @BpifrancePresse
About Omnes
Omnes is a leading Paris-based European investor in private equity and infrastructure. With more than €5 billion in assets under management, Omnes provides companies with the equity capital they need to grow through its four core businesses: Venture Capital, Buyout & Growth Capital, Infrastructure and Co-Investment. With more than 30 trade sales and nearly 15 IPOs in 20 years (including Themis Bioscience, Biovex, arGEN-X, Novaled and Direct Energie), Omnes Venture Capital team is a leading French player in financing innovative SMEs with dual expertise in the deep-tech and healthcare sectors. Omnes is committed to ESG issues and has set up the Omnes Foundation in aid of children’s charities. The company is also a signatory to the United Nations Principles for Responsible Investment (PRI). www.omnescapital.com
About UI Investissement
UI Investissement is an independent, specialized company in the development of unlisted French companies with €1.5 billion under management. For over 50 years, UI Investissement has been committed to work alongside the managers of growing SMEs and STIs to help them emerge as economically and sustainably successful businesses through its focus on three areas: health, agro-business, and business services.
With its expertise, UI Investissement provides support to companies in the health sector at all stages of their development and plays a central role in the ecosystem. It is through the Majycc Innovation Santé fund that UI Investissement supports entrepreneurs who aim to be the architects of tomorrow's health. The roots of Majycc Innovation Santé are deeply connected to the DNA of several private clinic groups, nursing home groups, and mutual health insurance companies, representing entrepreneurship, health and human values, respect for corporate culture, and the projects of the individuals who build them.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230314005169/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Peter Rauch Named President of Mountain Hardwear11.9.2026 01:00:00 CEST | Press release
Columbia Sportswear Company (Nasdaq: COLM), a leading innovator in active outdoor apparel, footwear, accessories and equipment, today announced that Peter Rauch will be the new President of the Mountain Hardwear brand. Mountain Hardwear's mission is to encourage and equip people to seek wilder paths. With over 30 years of wild wisdom, Mountain Hardwear continues to offer premium technical apparel, accessories and equipment products for climbers, mountaineers, skiers, snowboarders, and trail athletes. Troy Sicotte will transition to a new role as Global Vice President, Sales for Mountain Hardwear. Mr. Rauch transitions from his current role as General Manager of Columbia Brand North America and brings nearly 20 years of leadership experience across the Columbia family of brands, deep industry knowledge and a genuine passion for the outdoors. "Throughout his career, Peter has built strong cross-functional partnerships, developed high-performing teams, and delivered meaningful business re
The LYCRA Company Makes NSC Safety Congress & Expo Debut10.9.2026 19:45:00 CEST | Press release
Highlights Innovative Fibers That Enhance Worker Comfort, Performance, and Protection The LYCRA Company, a global leader in developing fiber and technology solutions for the apparel and personal care industries, today announced its inaugural exhibition at the NSC Safety Congress & Expo, being held September 14-16 in Indianapolis. The company also marks the North American debut of its “FIBERS THATWORK” portfolio of innovative solutions for workwear, uniforms, and protective apparel. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260910402207/en/ The LYCRA Company will debut its FIBERS THAT WORK portfolio at the NSC Safety Congress & Expo in Indianapolis, highlighting fiber technologies engineered to enhance comfort, durability, visibility, and protection in workwear and protective apparel. "Comfort is fundamental to workwear performance," said Tara Maurer-Mackay, product category director, branded specialty products at The LY
Turning Up the Heat: ProAmpac Helps Power Circle K’s Flamin’ Hot® Boneless Chicken Wings Launch10.9.2026 18:12:00 CEST | Press release
ProAmpac, a global leader in flexible packaging and material science, is proud to announce its role in supporting Circle K's launch of Flamin' Hot® Boneless Chicken Wings, created in partnership with PepsiCo/Frito-Lay. Designed to address key challenges in hot food packaging, ProAmpac's custom fiber-based tray helps maintain food quality, improve shelf appeal, and enhance the consumer experience. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260910495607/en/ Flamin' Hot Chicken Bites Circle K sought a better way to merchandise its Flamin’ Hot® Boneless Chicken Wings while addressing several performance challenges, including heat retention, moisture loss, and grease resistance, while extending hot hold time. ProAmpac responded with a custom tray designed specifically for the recipe and portion size, demonstrating its flexibility in meeting unique customer design and performance requirements. Working from PepsiCo’s initial br
Record Currency Management wins new FX Alpha and Frontier Market mandates10.9.2026 17:30:00 CEST | Press release
Record Currency Management Ltd (RCM), a subsidiary of London-listed Record plc (Record Financial Group), is pleased to announce that it has been awarded two new mandates of strategic importance – an FX Alpha mandate and an FX Frontier mandate. RCM is the UK currency management arm of Record Financial Group, the London-listed specialist investment group managing over USD 122 billion of assets on behalf of institutional clients worldwide. Record’s client base comprises pension funds, foundations, sovereign institutions and other asset managers, with whom the Group has built long-standing relationships through its focus on bespoke investment and risk management solutions. Headquartered in London, Record has offices in Hamburg, Zurich, Zug, New York, and Hong Kong. For institutional investors, currency can represent both a source of risk and a potential source of differentiated returns. Live since 2012, Record’s FX Alpha strategy aims to deliver attractive risk-adjusted returns without cap
Azizi Developments Introduces USD 8.1 Billion Master-Planned Community Azizi Florence in Sharjah10.9.2026 16:08:00 CEST | Press release
Azizi Developments, a leading private developer in the UAE, is unveiling Azizi Florence, a USD 8.1 billion master-planned community marking its first project in Sharjah. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260910091949/en/ Azizi Florence (Photo: AETOSWire) The freehold development will feature 1,130 villas, more than 6,000 townhouses and 3,500 apartments, with three-bedroom townhouses starting from USD 515,000 at USD 231 per square foot of sellable area. Designed as an integrated destination, Azizi Florence will bring together residential, retail, hospitality, education, leisure and wellness offerings, centred around a 1.7-million-square-foot Central Park. Six residential clusters will each feature a park, clubhouse, community centre and landscaped gardens. Mr. Mirwais Azizi, Founder and Chairman of Azizi Group, said: “Returning to Sharjah after more than three decades is deeply meaningful to me, as this emirate w
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom